News

Stay Up-To-Date on NEXT Oncology

  • All
  • NEXT Oncology Blog
  • NEXT Oncology News
  • Press Releases

Grand Opening of joint venture brings access to proprietary Phase I program to more patients

NEXT-Virginia Opens Phase I Clinical Research Clinic for Oncology Patients in collaboration with Virginia Cancer Specialists. (SAN ANTONIO) January 9, 2023 –– Dr. Alexander I. Spira of Virginia Cancer Specialists (VCS) …

ONXEO provides update on the Development Program for its first-in-class drug candidate AsiDNATM

Paris (France), January 25th, 2023 – 6pm CET – Onxeo S.A. (Euronext Growth Paris: ALONX), hereafter “Onxeo” or the “Company”, a clinical-stage biotechnology company specializing in the development of innovative tumor …

ADCs in Breast Oncology: Present & Future

Research remains an essential part of cancer care. In this blog, we will provide information about recent updates or new approvals as it applies to breast cancer written by Dr. …

Pregnancy Outcome & Safety of Interrupting Therapy for Women with Endocrine ResponsIVE Breast Cancer.

Research remains an essential part of cancer care. In this blog, we will provide information about recent updates or new approvals as it applies to breast cancer written by Dr. …

A New Paradigm in Breast Cancer Treatment: Treating HER 2 NEU Low-Expressing Breast cancer

Research remains an essential part of cancer care. In this blog, we will provide information about recent updates or new approvals as it applies to breast cancer written by Dr. …

Pregnancy and Breast Cancer

Research remains an essential part of cancer care. In this blog, we will provide information about recent updates or new approvals as it applies to breast cancer written by Dr. …

Teon Therapeutics Announces First Patient Treated in Phase 1/2 Clinical Trial of TT-816, a Novel Oral Immune Checkpoint Inhibitor, in Patients with Advanced Solid Tumors

SAN FRANCISCO, November 1, 2022 – Teon Therapeutics (Teon), a clinical-stage biopharmaceutical company targeting metabolic signaling pathways and pioneering the development of G-Protein Coupled Receptor (GPCR) immuno-oncology therapies in difficult-to-treat …

Teon Therapeutics Announces First Patient Treated in Phase 1/2 Clinical Trial of TT-816, a Novel Oral Immune Checkpoint Inhibitor, in Patients with Advanced Solid Tumors

Multi-center Phase 1/2 study to evaluate safety and efficacy of TT-816, an oral CB2 receptor antagonist acting as an immune checkpoint inhibitor while promoting T cell infiltration of cold tumors …

The Theresa Mays Endowed Merit Award Established for Promising Investigators Holding a PharmD Degree

(SAN ANTONIO) November 1, 2022 –– The Theresa Mays Endowed Merit Award has been established to promote the education and advancement of oncology research for pharmacists. The award has been …

Timing of Postmastectomy Radiotherapy Following Adjuvant Chemotherapy for High-Risk Breast Cancer: A Post Hoc Analysis of a Randomized Controlled Clinical Trial. Chen, Si-Ye eta al.

Research remains an essential part of cancer care. In this blog, we will provide information about recent updates or new approvals as it applies to breast cancer written by Dr. …